DE602004019296D1 - Polymorphe Formen von Rifaximin als Antibiotica - Google Patents

Polymorphe Formen von Rifaximin als Antibiotica

Info

Publication number
DE602004019296D1
DE602004019296D1 DE602004019296T DE602004019296T DE602004019296D1 DE 602004019296 D1 DE602004019296 D1 DE 602004019296D1 DE 602004019296 T DE602004019296 T DE 602004019296T DE 602004019296 T DE602004019296 T DE 602004019296T DE 602004019296 D1 DE602004019296 D1 DE 602004019296D1
Authority
DE
Germany
Prior art keywords
rifaximin
antibiotics
polymorphic forms
polymorphic
forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004019296T
Other languages
English (en)
Inventor
Giuseppe C Viscomi
Manuela Campana
Dario Braga
Donatella Confortini
Vincenzo Cannata
Denis Severini
Paolo Righi
Goffredo Rosini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfa Wasserman SpA
Original Assignee
Alfa Wasserman SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33187382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602004019296(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wasserman SpA filed Critical Alfa Wasserman SpA
Publication of DE602004019296D1 publication Critical patent/DE602004019296D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1236—Cooking devices induction cooking plates or the like and devices to be used in combination with them adapted to induce current in a coil to supply power to a device and electrical heating devices powered in this way
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1245—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements
    • H05B6/1263—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements using coil cooling arrangements

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Electromagnetism (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
DE602004019296T 2003-11-07 2004-03-09 Polymorphe Formen von Rifaximin als Antibiotica Expired - Lifetime DE602004019296D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT002144A ITMI20032144A1 (it) 2003-11-07 2003-11-07 Forme polimorfe di rifaximina, processi per ottenerle e

Publications (1)

Publication Number Publication Date
DE602004019296D1 true DE602004019296D1 (de) 2009-03-19

Family

ID=33187382

Family Applications (4)

Application Number Title Priority Date Filing Date
DE602004006367.3T Expired - Lifetime DE602004006367C5 (de) 2003-11-07 2004-03-09 Polymorphe Form von Rifaximin als Antibiotikum
DE04005541T Pending DE04005541T1 (de) 2003-11-07 2004-03-09 Polymorphe Formen von Rifaximin als Antibiotika
DE602004019298T Expired - Lifetime DE602004019298D1 (de) 2003-11-07 2004-03-09 Polymorphe Formen von Rifaximin als Antibiotica
DE602004019296T Expired - Lifetime DE602004019296D1 (de) 2003-11-07 2004-03-09 Polymorphe Formen von Rifaximin als Antibiotica

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DE602004006367.3T Expired - Lifetime DE602004006367C5 (de) 2003-11-07 2004-03-09 Polymorphe Form von Rifaximin als Antibiotikum
DE04005541T Pending DE04005541T1 (de) 2003-11-07 2004-03-09 Polymorphe Formen von Rifaximin als Antibiotika
DE602004019298T Expired - Lifetime DE602004019298D1 (de) 2003-11-07 2004-03-09 Polymorphe Formen von Rifaximin als Antibiotica

Country Status (38)

Country Link
US (5) US7045620B2 (de)
EP (6) EP1557421B1 (de)
JP (5) JP2005139161A (de)
KR (4) KR20050043589A (de)
CN (4) CN1613858A (de)
AR (3) AR043547A1 (de)
AT (3) ATE361927T1 (de)
AU (2) AU2004200964A1 (de)
BR (2) BRPI0402382A (de)
CA (2) CA2460384A1 (de)
CL (1) CL2004000498A1 (de)
CO (1) CO5560083A1 (de)
CY (3) CY1108017T1 (de)
DE (4) DE602004006367C5 (de)
DK (3) DK1676848T3 (de)
ES (3) ES2320161T3 (de)
HK (3) HK1092150A1 (de)
HR (2) HRP20040265A2 (de)
IL (2) IL160798A0 (de)
IT (1) ITMI20032144A1 (de)
JO (1) JO2470B1 (de)
MA (1) MA27069A1 (de)
MD (1) MD3653G8 (de)
ME (1) ME00424B (de)
MX (2) MXPA04002353A (de)
NO (1) NO334950B1 (de)
NZ (1) NZ531622A (de)
PL (3) PL1676848T3 (de)
PT (3) PT1557421E (de)
RS (4) RS54569B1 (de)
RU (1) RU2270200C2 (de)
SI (3) SI1557421T1 (de)
TN (2) TNSN04044A1 (de)
TW (1) TWI285107B (de)
UA (1) UA86384C2 (de)
WO (1) WO2005044823A2 (de)
YU (1) YU24804A (de)
ZA (1) ZA200401948B (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
DK1698630T3 (da) 2005-03-03 2014-12-08 Alfa Wassermann Spa Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
CN104382900A (zh) 2006-08-02 2015-03-04 萨利克斯药品公司 治疗放射性肠炎的组合物和方法
ITMI20061692A1 (it) * 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
US8633234B2 (en) * 2006-09-22 2014-01-21 Cipla Limited Rifaximin
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
WO2009008005A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
AU2016203925B2 (en) * 2007-07-06 2016-10-20 Lupin Limited Pharmaceutical compositions of rifaximin
SI2011486T1 (sl) * 2007-07-06 2012-10-30 Lupin Ltd Farmacevtski sestavki rifaksimina
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
UA101829C2 (uk) * 2008-02-25 2013-05-13 Саликс Фармасьютикалз, Лтд. ФОРМА η РИФАКСИМІНУ І ЇЇ ЗАСТОСУВАННЯ В ТЕРАПЕВТИЧНІЙ ПРАКТИЦІ
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
PL2252148T3 (pl) * 2008-02-26 2019-09-30 Salix Pharmaceuticals, Ltd. Sposoby leczenia zespołu jelita drażliwego
SI2294012T1 (sl) 2008-05-07 2014-11-28 Salix Pharmaceuticals, Ltd. Dajanje ÄŤistila za ÄŤrevo in antibiotika za zdravljenje ÄŤrevesne bolezni
KR20110071096A (ko) 2008-09-26 2011-06-28 아스카 세이야쿠 가부시키가이샤 기능성 소화관 장해의 예방 및/또는 치료제
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20100317681A1 (en) * 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
WO2010040020A1 (en) 2008-10-02 2010-04-08 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
WO2010067072A1 (en) 2008-12-10 2010-06-17 Cipla Limited Rifaximin complexes
IT1397617B1 (it) * 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
EP3964066A1 (de) 2009-06-02 2022-03-09 Salix Pharmaceuticals, Ltd. Verfahren zur behandlung von hepatischer enzephalopathie
JP2013504597A (ja) 2009-09-13 2013-02-07 サリックス ファーマスーティカルズ，リミテッド 過敏性腸症候群（ｉｂｓ）の治療方法
MX346660B (es) * 2009-10-27 2017-03-28 Lupin Ltd Dispersion solida de rifaximina.
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
MX2012005883A (es) 2009-11-23 2012-10-09 Cipla Ltd Composicion topica en espuma.
US8952159B2 (en) † 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
WO2011103246A1 (en) 2010-02-18 2011-08-25 Salix Pharmaceuticals, Ltd. Methods for treating infection
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
BR112012030783A2 (pt) * 2010-06-03 2015-09-29 Salix Pharmaceuticals Ltd formas de rifaximina e seus usos
EP2582707A4 (de) * 2010-06-16 2014-01-08 Apotex Pharmachem Inc Polymorphe formen von rifaximin
WO2012009388A1 (en) * 2010-07-12 2012-01-19 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
US8759513B2 (en) 2010-09-13 2014-06-24 Sequent Scientific Limited Polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012060675A1 (es) * 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Proceso para la preparación de rifaximina amorfa
WO2012076832A1 (en) * 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
CA2825964A1 (en) * 2011-02-11 2012-08-16 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
CA2834829A1 (en) 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
WO2013067394A1 (en) 2011-11-02 2013-05-10 Salix Pharmaceuticals, Ltd Methods for treating irritable bowel syndrome (ibs) and infections
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
CA2876737A1 (en) * 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US9849090B2 (en) 2012-12-12 2017-12-26 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of rifaximin
WO2014140995A2 (en) 2013-03-15 2014-09-18 Alfa Wassermann S.P.A. Method for diagnosing vaginal infections
EA201591267A1 (ru) 2013-03-15 2016-03-31 Альфа Вассерманн С.П.А. Рифаксимин для применения в лечении вагинальных инфекций
ES2829285T3 (es) 2013-04-12 2021-05-31 Alfasigma Spa Administración de AINE y composiciones, métodos y sistemas relacionados
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
ES2621557T3 (es) * 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
WO2015159275A2 (en) * 2014-04-19 2015-10-22 Granules India Limited An improved process for the preparation of rifamycin derivatives
CA2947962C (en) 2014-05-04 2024-01-16 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
ES2810010T3 (es) 2014-05-12 2021-03-08 Alfasigma Spa Preparación y uso de la forma cristalina tau de rifaximina solvatada con DEGME
WO2016003536A1 (en) * 2014-06-30 2016-01-07 Salix Pharmaceuticals, Inc. Methods for retreating irritable bowel syndrome (ibs)
CN104083324B (zh) * 2014-07-10 2017-05-10 青岛动保国家工程技术研究中心有限公司 一种利福昔明的兽用悬乳剂及其制备方法和应用
EP2982764A1 (de) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identifizierung von Vaginalbakterien
CN104274391B (zh) * 2014-10-08 2017-02-01 哈尔滨坤盟医药科技有限公司 一种含利福昔明的药物制剂
WO2017021975A1 (en) * 2015-08-06 2017-02-09 Msn Laboratories Private Limited Process for the preparation of crystalline forms of rifaximin
US10576065B2 (en) 2016-03-24 2020-03-03 Sandoz Ag Pharmaceutical composition containing rifaximin alpha and delta
EP3373914B2 (de) 2016-03-24 2022-06-01 Sandoz AG Lagerstabile zusammensetzung mit rifaximin-alpha
US9988398B2 (en) * 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
EP4137132A1 (de) 2016-09-30 2023-02-22 Salix Pharmaceuticals, Inc. Feste dispersionsformen von rifaximin
CN106632396B (zh) * 2017-01-06 2019-01-11 成都樵枫科技发展有限公司 γ晶型利福昔明的制备方法和用途
CA3013161C (en) * 2017-04-26 2020-03-24 Sandoz Ag Oral dosage form comprising rifaximin in form beta
PL3645539T3 (pl) 2017-06-26 2021-10-25 Biofer S.P.A. Pochodne pirydoimidazoryfamycyny jako środek przeciwbakteryjny
CA3142214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
AU2020355603A1 (en) 2019-09-24 2022-03-17 Bausch Health Ireland Limited Rifaximin liquid formulations
WO2021191312A1 (en) 2020-03-24 2021-09-30 Bausch Health Ireland Limited Methods of treating covid-19 with rifaximin
WO2021229480A1 (en) * 2020-05-15 2021-11-18 Atra Pharmaceuticals Limited Polymorph of rifaximin, process for the preparation thereof and pharmaceutical composition containing rifaximin
CA3184054A1 (en) 2020-06-26 2021-12-30 Jacob Cole Targeted release rifaximin compositions
WO2022090490A1 (en) 2020-10-29 2022-05-05 Bausch Health Ireland Limited Rifaximin liquid formulations for use in the treatment of sickle cell disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241785A (en) * 1978-07-24 1980-12-30 Peerless Of America, Inc. Heat exchangers and method of making same
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
CA2082809C (en) * 1990-06-29 1995-10-17 Marino Nebuloni Pure crystalline form of rifapentine
NZ519984A (en) * 2000-01-07 2004-03-26 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
AU2002212340B2 (en) * 2000-10-31 2006-12-14 Sandoz Ag Crystalline forms of venlafaxine hydrochloride
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20050262269A1 (en) 2004-05-20 2005-11-24 Pike Jimmy D System and method for information handling system PCI express advanced switching
DK1698630T3 (da) 2005-03-03 2014-12-08 Alfa Wassermann Spa Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater
US8633234B2 (en) * 2006-09-22 2014-01-21 Cipla Limited Rifaximin
WO2008115572A1 (en) 2007-03-21 2008-09-25 Theraquest Biosciences, Inc. Methods and compositions of nsaids
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
WO2009008005A1 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
SI2011486T1 (sl) 2007-07-06 2012-10-30 Lupin Ltd Farmacevtski sestavki rifaksimina
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
JP2011500552A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
UA101829C2 (uk) 2008-02-25 2013-05-13 Саликс Фармасьютикалз, Лтд. ФОРМА η РИФАКСИМІНУ І ЇЇ ЗАСТОСУВАННЯ В ТЕРАПЕВТИЧНІЙ ПРАКТИЦІ

Also Published As

Publication number Publication date
EP1682556A2 (de) 2006-07-26
DE602004006367T2 (de) 2007-09-06
BRPI0407149A (pt) 2006-02-07
DE602004006367C5 (de) 2019-04-04
KR100867751B1 (ko) 2008-11-10
RU2270200C2 (ru) 2006-02-20
CY1108909T1 (el) 2014-07-02
WO2005044823A2 (en) 2005-05-19
ES2244364T3 (es) 2007-12-01
DE602004019298D1 (de) 2009-03-19
CN101260114A (zh) 2008-09-10
CA2538546C (en) 2011-04-19
CA2460384A1 (en) 2005-05-07
JO2470B1 (en) 2009-01-20
DK1676848T3 (da) 2009-05-11
BRPI0402382A (pt) 2005-06-28
YU24804A (sh) 2006-08-17
EP1676848A1 (de) 2006-07-05
HRP20060093B1 (hr) 2015-12-18
NZ531622A (en) 2004-10-29
HRP20060093A2 (en) 2006-05-31
ES2320161T3 (es) 2009-05-19
CN101260114B (zh) 2012-11-28
ES2320160T4 (es) 2011-03-09
AR081992A2 (es) 2012-10-31
US20050272754A1 (en) 2005-12-08
EP2210893A1 (de) 2010-07-28
ATE421966T1 (de) 2009-02-15
KR100855084B1 (ko) 2008-08-29
IL174271A (en) 2010-12-30
JP5635376B2 (ja) 2014-12-03
JP2011057698A (ja) 2011-03-24
MXPA06002644A (es) 2006-06-06
EP1676848B1 (de) 2009-01-28
MXPA04002353A (es) 2005-05-11
SI1676848T1 (sl) 2009-06-30
RS20150291A1 (en) 2015-10-30
EP1676847A1 (de) 2006-07-05
MD3653F2 (en) 2008-07-31
PT1676847E (pt) 2009-04-09
DK1676847T3 (da) 2009-05-11
JP2007509904A (ja) 2007-04-19
US7915275B2 (en) 2011-03-29
US20050101598A1 (en) 2005-05-12
AU2004200964A1 (en) 2005-05-26
US8404704B2 (en) 2013-03-26
PT1557421E (pt) 2007-07-31
US8173801B2 (en) 2012-05-08
SI1676847T1 (sl) 2009-06-30
ATE361927T1 (de) 2007-06-15
MA27069A1 (fr) 2004-12-20
RS54568B1 (en) 2016-06-30
DK1557421T3 (da) 2007-09-17
RS54569B1 (en) 2016-06-30
CA2538546A1 (en) 2005-05-19
ME00424B (me) 2011-10-10
DE602004006367D1 (de) 2007-06-21
ITMI20032144A1 (it) 2005-05-08
CL2004000498A1 (es) 2005-03-11
EP1676847B1 (de) 2009-01-28
KR20070113327A (ko) 2007-11-28
CN1613858A (zh) 2005-05-11
JP2011046738A (ja) 2011-03-10
CN1886408B (zh) 2010-06-09
US20110160449A1 (en) 2011-06-30
IL174271A0 (en) 2006-08-01
SI1557421T1 (sl) 2007-08-31
JP5199576B2 (ja) 2013-05-15
PT1676848E (pt) 2009-04-09
CN101260115A (zh) 2008-09-10
HK1073657A1 (en) 2005-10-14
KR20060110737A (ko) 2006-10-25
CO5560083A1 (es) 2005-09-30
CY1108017T1 (el) 2013-09-04
HK1092151A1 (en) 2007-02-02
AU2004287601A1 (en) 2005-05-19
DE04005541T1 (de) 2005-12-29
PL1676847T3 (pl) 2009-07-31
UA86384C2 (uk) 2009-04-27
EP2208730A1 (de) 2010-07-21
KR100883216B1 (ko) 2009-02-13
US7045620B2 (en) 2006-05-16
KR20050043589A (ko) 2005-05-11
CY1108964T1 (el) 2014-07-02
TNSN04044A1 (en) 2006-06-01
IL160798A0 (en) 2004-08-31
AR081991A2 (es) 2012-10-31
TNSN06069A1 (en) 2007-10-03
RS20150292A1 (en) 2015-10-30
HK1092150A1 (en) 2007-02-02
ES2320160T3 (es) 2009-05-19
HRP20040265A2 (en) 2004-12-31
RS20060168A (en) 2008-09-29
MD3653G8 (ro) 2016-08-31
TWI285107B (en) 2007-08-11
CN1886408A (zh) 2006-12-27
BRPI0407149A8 (pt) 2019-01-15
NO334950B1 (no) 2014-08-04
ZA200401948B (en) 2004-04-29
RU2004108953A (ru) 2005-10-27
EP1557421B1 (de) 2007-05-09
US20080132530A1 (en) 2008-06-05
RS54571B1 (en) 2016-06-30
PL1676848T3 (pl) 2009-07-31
WO2005044823A3 (en) 2005-10-27
KR20070113326A (ko) 2007-11-28
TW200515913A (en) 2005-05-16
NO20061110L (no) 2006-04-19
JP2005139161A (ja) 2005-06-02
AU2004287601B8 (en) 2009-03-05
ES2244364T1 (es) 2005-12-16
JP2014177500A (ja) 2014-09-25
CN101260115B (zh) 2011-11-23
AU2004287601B2 (en) 2009-02-26
PL1557421T3 (pl) 2007-08-31
MD20060080A (en) 2006-11-30
US20120059023A1 (en) 2012-03-08
ATE421965T1 (de) 2009-02-15
EP1557421A1 (de) 2005-07-27
AR043547A1 (es) 2005-08-03

Similar Documents

Publication Publication Date Title
DE602004019296D1 (de) Polymorphe Formen von Rifaximin als Antibiotica
ECSP066436A (es) Compuestos heterociclicos fusionados
IS8513A (is) Lífræn efnasambönd
SE0301569D0 (sv) Novel compounds
NO20055688D0 (no) Organiske forbindelser
DE602004015724D1 (de) Diazepinoindolderivate als kinaseinhibitoren
DK1605897T3 (da) Polyethelen-glycol-link-glp-1-forbindelser
IS8108A (is) Ný efnasambönd
IS8228A (is) Ný asetídínefnasambönd
IS8089A (is) Efnasambönd
IS8292A (is) Ný efnasambönd
NO20043586L (no) Fremgangsmate for fremstilling av organiske forbindelser
ATE463248T1 (de) Cephem-verbindungen
DE602004004295D1 (de) 6-ä(substituiertes)phenylütriazolopyrimidine als antikrebsmittel
ATE394372T1 (de) G-lactamderivate als prostaglandinagonisten
DK1651034T4 (da) Organiske forbindelser
SE0202495L (sv) Förstärkning av vevhus
ATE499348T1 (de) Stabiler polymorph von bifeprunoxmesilat
DK1473466T3 (da) Teleskopcylinder
DE602004013817D1 (de) Über farbwerk angetriebene wellenlose einheit
NO20031736D0 (no) Forbindelser
NO20055170D0 (no) Organiske forbindelser
NO20035034L (no) Vertikal installasjon av en langstrakt prosess-enhet
DE502004012380D1 (de) Bekleidungsstück
SE0301851D0 (sv) Immunomodulatory compounds

Legal Events

Date Code Title Description
8364 No opposition during term of opposition